729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients

BACKGROUND: Bezlotoxumab has been shown to prevent recurrent episodes of C. difficile infection (CDI) in high risk patients. Current studies define therapeutic efficacy within the first 12 weeks when the risk of recurrence is greatest. However, the risk of recurrent CDI can occur beyond the 12-week...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Open Forum Infect Dis
Päätekijät: Perreault, Sarah, Schiffer, Molly, Ruggero, Michael, McManus, Dayna, Topal, Jeffrey E
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Poster Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777471/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.921
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia